Cantor Fitzgerald Starts Humana (HUM) at Buy; Medicare Is A Large Opportunity
Tweet
Share
E-mailGet Alerts HUM Hot Sheet
Price: $380.73 +0.72%
Rating Summary:
15 Buy, 19 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
15 Buy, 19 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Cantor Fitzgerald initiates coverage on Humana (NYSE: HUM) with a Buy. PT $95.00.
Analyst, Joseph D. France, said, "Although its commercial business is relatively weak, Humana's large Medicare book is growing rapidly because of baby boomers aging into Medicare and choosing managed care, and the company's long-term strategy of reinvesting in more cost effective products that preserve the benefits its members find most attractive. This strategy, leveraged by greater consumer engagement, has also fostered better medical management. This has proven a competitive advantage as the government has implemented a program to cut Medicare Advantage reimbursement by 15% over a period of years."
For an analyst ratings summary and ratings history on Humana click here. For more ratings news on Humana click here.
Shares of Humana closed at $79.32 yesterday.
Analyst, Joseph D. France, said, "Although its commercial business is relatively weak, Humana's large Medicare book is growing rapidly because of baby boomers aging into Medicare and choosing managed care, and the company's long-term strategy of reinvesting in more cost effective products that preserve the benefits its members find most attractive. This strategy, leveraged by greater consumer engagement, has also fostered better medical management. This has proven a competitive advantage as the government has implemented a program to cut Medicare Advantage reimbursement by 15% over a period of years."
For an analyst ratings summary and ratings history on Humana click here. For more ratings news on Humana click here.
Shares of Humana closed at $79.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight
- BMO Capital Starts AMD (AMD) at Outperform
- Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
